Skip to content

LSD: all studies

Page 193 of 282: studies 1,921 to 1,930 of 2,816, newest first. Back to the LSD overview

Research

Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists

Current Psychiatry Research and Reviews January 21, 2024 Payal Ghosh, Debjeet Sur 1 citation

: Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems. They are frequently regarded to be physically safe and do not frequently lead to dependency or addiction. The use of psychedelic substances in the treatment of mental illness and the adoption of the Substance Act of 1970 has classified psychedelic...

Psychedelics for mental health: a biochemical perspective

The Biochemist January 19, 2024 Javier González-Maeso

Psychedelics, such as psilocybin, mescaline and lysergic acid diethylamide (LSD), are psychoactive substances that induce alterations in cognition, perception and sensory processing. Studies in rodent models and healthy human volunteers highlight the serotonin 5-HT2A receptor’s pivotal role in mediating hallucinogenic effects. More recent findings indicate that psychedelics induce lasting...

Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review.

The Primary Care Companion For CNS Disorders January 16, 2024 David F Lo, Hasan Zia, Pranetha Rajkumar et al. 6 citations

Objective: To investigate the relationship between psychedelic microdosing and its effects on mental health, aiming to understand if microdosing can improve mental well-being. Data Sources: PubMed and Scopus were searched on December 25, 2022, using search terms related to psychedelics, microdosing, and mental health. The inclusion criteria focused on studies published between January 1, 2012,...

A choroid plexus apocrine secretion mechanism shapes CSF proteome and embryonic brain development.

bioRxiv : the preprint server for biology January 16, 2024 Ya'El Courtney, Joshua P Head, Elizabeth D Yimer et al. 9 citations preprint

We discovered that apocrine secretion by embryonic choroid plexus (ChP) epithelial cells contributes to the cerebrospinal fluid (CSF) proteome and influences brain development in mice. The apocrine response relies on sustained intracellular calcium signaling and calpain-mediated cytoskeletal remodeling. It rapidly alters the embryonic CSF proteome, activating neural progenitors lining the...

DOI: 10.1101/2024.01.08.574486 (opens in new tab) Full text (opens in new tab) Maternal health Fetal development Brain physiology Developmental biology

Synthetic surprise as the foundation of the psychedelic experience

Neuroscience & Biobehavioral Reviews January 15, 2024 Dietmar Schmitz, Roberto De Filippo 13 citations

Psychedelic agents, such as LSD and psilocybin, induce marked alterations in consciousness via activation of the 5-HT2A receptor (5-HT2ARs). We hypothesize that psychedelics enforce a state of synthetic surprise through the biased activation of the 5-HTRs system. This idea is informed by recent insights into the role of 5-HT in signaling surprise. The effects on consciousness, explained by the...

DOI: 10.1016/j.neubiorev.2024.105538 (opens in new tab) Psilocybin Predictive coding Surprise Perception +4

Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins

Journal of Psychopharmacology January 12, 2024 Antonin Rouaud, Gregor Hasler, Abigail E. Calder 36 citations

Though microdosing psychedelics has become increasingly popular, its long-term effects on cardiac health remain unknown. Microdosing most commonly involves ingesting sub-threshold doses of lysergic acid diethylamide (LSD), psilocybin, or other psychedelic drugs 2–4 times a week for at least several weeks, but potentially months or years. Concerningly, both LSD and psilocybin share structural...

Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.

Neuroscience Applied January 11, 2024 Drummond E-Wen Mcculloch, Matthias E. Liechti, Kim Pc Kuypers et al. 10 citations

Psychedelic drugs including psilocybin and LSD are undergoing clinical trials for a range of psychiatric and neurological conditions, and have particularly shown substantial promise in phase 2 studies of depression. In this article we outline key knowledge gaps that may be imperative for a successful implementation of psychedelic drugs as medicines as identified by members of the European...

DOI: 10.1016/j.nsa.2024.103938 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted therapy Psychedelic treatment Psychedelic therapeutics Psychedelics for therapy +19

Perceptual Modifying Compounds and Their Potential Therapeutic Applications in Neuropsychiatric Disorders.

ACS Medicinal Chemistry Letters January 11, 2024 Robert B. Kargbo 1 citation

Psychedelic compounds, including ketamine and LSD, have gained renewed interest as potential treatments for neuropsychiatric disorders. These compounds act as psychoplastogens, promoting neuronal growth by activating AMPA receptors, TrkB, and mTOR. The prefrontal cortex plays a crucial role in their therapeutic effects through top-down control over brain regions involved in motivation, fear,...

DOI: 10.1021/acsmedchemlett.3c00535 (opens in new tab) Full text (opens in new tab) Psychedelics Mental-health Brain-plasticity Therapeutic-medicine

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

Current Neuropharmacology January 5, 2024 Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic et al. 73 citations

Abstract: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs))....

Psychedelic Renaissance

UC Merced Undergraduate Research Journal 2024 Jose Miranda

Psychedelic substances, which were once categorized as Schedule 1 drugs, are gaining public attention for their potential to treat individuals with mental conditions. Every Schedule 1 drug was once considered to have no medicinal value, with the potential for high abuse, but recent research has suggested otherwise. LySergic acid Diethylamide (LSD) and MethyleneDioxy-MethAmphetamine (MDMA) are...